What is the recommended management for insulin resistance?

Management of Insulin Resistance

Begin with lifestyle modification targeting 5-10% weight loss combined with immediate initiation of metformin 500 mg daily, titrating gradually while monitoring response every 3-6 months, and intensify therapy promptly with GLP-1 receptor agonists or SGLT2 inhibitors if goals are not met. 1, 2, 3

Lifestyle Modification: The Foundation of Treatment

Weight loss of 5-10% of initial body weight is the single most effective intervention for improving insulin sensitivity and must be prioritized in all overweight or obese patients. 1, 2, 3

Caloric Restriction

• Prescribe a daily caloric deficit of 500-1,000 kcal to achieve 1-2 pounds per week weight loss 1, 3
• This structured approach produces long-term weight loss that significantly improves insulin sensitivity independent of mechanism 3

Exercise Prescription

• Perform at least 150 minutes per week of moderate-intensity aerobic activity (50-70% maximum heart rate), spread over at least 3 days with no more than 2 consecutive days without exercise 1, 2, 3
• Add resistance training 2-3 times per week on non-consecutive days, engaging all major muscle groups—this improves insulin sensitivity equal to or greater than aerobic exercise alone 1, 2, 3
• Interrupt prolonged sedentary periods with light activity every 30 minutes 1
• For children and adolescents, prescribe at least 60 minutes of daily physical activity 3

Dietary Modifications

• Limit saturated fat intake to <7% of total calories 1, 2, 3
• Emphasize complex carbohydrates with low glycemic index, providing at least 14 g fiber per 1,000 kcal 2, 3
• Follow a Mediterranean-style diet rich in monounsaturated and polyunsaturated fats to improve glucose metabolism and reduce cardiovascular risk 4, 2
• Eliminate sugar-sweetened beverages and minimize foods with added sugars 4, 2
• Prioritize vegetables, fruits, legumes, whole grains, and dairy products with emphasis on higher fiber and lower glycemic load 4

First-Line Pharmacologic Therapy

Metformin is the preferred first-line agent (Grade A evidence) and should be initiated at diagnosis together with lifestyle changes, not delayed. 1, 2, 3

Metformin Initiation and Titration

• Begin at 500 mg once daily with food to minimize gastrointestinal adverse effects 1, 2, 3
• Increase by 500 mg every 1-2 weeks, targeting an ideal dose of 2,000 mg daily in divided doses 3
• Take medication with food or 15 minutes after a meal if symptoms persist 4
• Continue metformin when additional agents (including insulin) are added because of its ongoing metabolic benefits 1, 2
• Monitor serum vitamin B12 annually in patients receiving metformin 1

Common Pitfall

If gastrointestinal side effects do not resolve over a few weeks, follow up with the healthcare provider rather than discontinuing the medication 4

Treatment Intensification

Do not postpone intensification of therapy if glycemic or metabolic goals are not met after 3-6 months of metformin plus lifestyle intervention. 1, 2, 3

Second-Line Agents

• If HbA1c remains above target after 3-6 months, add either a GLP-1 receptor agonist or an SGLT2 inhibitor 1, 2
• For patients with chronic kidney disease and eGFR ≥30 mL/min/1.73 m², an SGLT2 inhibitor is specifically recommended 1
• GLP-1 receptor agonists provide additional weight loss benefit (1-2% HbA1c reduction expected) but do not fully normalize insulin sensitivity despite impressive weight loss 5, 6
• Encourage muscle-strengthening activities in patients using GLP-1 receptor agonists to mitigate loss of lean body mass 1

Thiazolidinediones: The True Insulin Sensitizers

• Thiazolidinediones are the only true direct insulin-sensitizing drugs available 5
• However, pioglitazone is associated with 2-4 kg weight gain, peripheral edema, increased risk of congestive heart failure, and fractures in women—use with caution 1
• Despite their potent insulin-sensitizing effects, side effects have limited widespread use 5

Populations Requiring Early Intensive Management

Initiate combination therapy with metformin and lifestyle modification immediately in patients with: 1, 2

• Body mass index ≥35 kg/m²
• Fasting plasma glucose 110-125 mg/dL
• 2-hour oral glucose tolerance test 173-199 mg/dL
• HbA1c ≥6.0%
• History of gestational diabetes

Special Population Considerations

Severe Insulin Resistance

• For patients requiring very high insulin doses (>2 units/kg body weight or >200 units/day), consider concentrated insulin preparations: U-500 regular insulin, U-300 glargine, U-200 degludec, or U-200 lispro 3, 7
• U-500 regular insulin is available in both prefilled pens and vials; other concentrated insulins are available only in prefilled pens to minimize dosing errors 3
• Consider combination products (insulin degludec/liraglutide or insulin glargine/lixisenatide) for patients requiring both basal insulin and GLP-1 receptor agonist therapy 3

Older Adults (≥65-70 years)

• Focus on drug safety, prioritizing strategies that minimize hypoglycemia risk, heart failure, renal dysfunction, bone fractures, and drug-drug interactions 3
• Less stringent glycemic targets (HbA1c <7.5-8.0%) may be appropriate for elderly patients with long-standing or complicated disease 3

Pregnancy

• Insulin is the preferred medication for treating hyperglycemia in pregnancy 3
• Target fasting glucose <95 mg/dL and either 1-hour postprandial <140 mg/dL or 2-hour postprandial <120 mg/dL 3

Diabetic Complications

• For proliferative diabetic retinopathy or severe non-proliferative diabetic retinopathy, avoid vigorous aerobic or resistance exercise that may trigger vitreous hemorrhage or retinal detachment 3
• In severe peripheral neuropathy, avoid treadmill, prolonged walking, jogging, and step exercises; instead recommend swimming, bicycling, rowing, and chair exercises 3

Monitoring and Follow-Up

• Measure HbA1c every 3 months until target is reached, then at least twice yearly 1, 2, 3
• Review medication regimen and adherence every 3-6 months 1, 2
• Expect HbA1c reduction of 0.7-1.0% with each additional oral agent added to metformin, and 1-2% with GLP-1 receptor agonists 1, 2
• Assess fasting glucose, lipid profile, and blood pressure as markers of insulin resistance improvement 2, 3
• Comprehensive cardiovascular risk reduction must remain a major focus of therapy, as insulin resistance is strongly associated with cardiovascular disease, hypertension, and dyslipidemia 3

Critical Clinical Pearls

• There is no standard meal plan that works universally for all patients—individualize macronutrient distribution while keeping total calorie and metabolic goals in mind 4
• Dietary supplementation with vitamins, minerals, herbs, or spices is not recommended for patients without underlying deficiencies, and there may be safety concerns with long-term antioxidant supplements 4
• Adults who drink alcohol should limit consumption to no more than one drink per day for women and two drinks per day for men, with awareness of delayed hypoglycemia risk when taking insulin or insulin secretagogues 4
• For patients presenting with significant hyperglycemic symptoms, markedly elevated plasma glucose, or HbA1c ≥10%, consider insulin therapy from the outset 3